The Medical Cannabis and Wellness ETF PM says GW Pharma deal validates pharmaceutical cannabinoids
The Medical Cannabis and Wellness ETF PM says GW Pharma deal validates pharmaceutical cannabinoids
The Medical Cannabis and Wellness UCITS ETF (LON:CBDP) Portfolio Manager Nawan Butt offers his thoughts on the recent $7.2B acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals, and how this deal will affect the medical cannabis sector.
GW Pharmaceuticals makes up 14% of the Medical Cannabis and Wellness UCITS ETF’s portfolio. The fund, that falls under the HANetf umbrella, recently celebrated its one year anniversary, has delivered a return of 39.47% over the past three months and 40.41% over the last 12 months.
